Ontology highlight
ABSTRACT:
SUBMITTER: Bahcall M
PROVIDER: S-EPMC5140694 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Bahcall Magda M Sim Taebo T Paweletz Cloud P CP Patel Jyoti D JD Alden Ryan S RS Kuang Yanan Y Sacher Adrian G AG Kim Nam Doo ND Lydon Christine A CA Awad Mark M MM Jaklitsch Michael T MT Sholl Lynette M LM Jänne Pasi A PA Oxnard Geoffrey R GR
Cancer discovery 20160930 12
Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). However, the landscape of MET-specific targeting agents remains underdeveloped, and understanding of mechanisms of resistance to MET TKIs is limited. Here, we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded drama ...[more]